


=> d l14
 L14 HAS NO ANSWERS
 L14 STR



VPA 17-21/22/20/19 U
 NODE ATTRIBUTES:
 NSPEC IS R AT 16
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 16 4 8
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

=> s l14 ful
 FULL SEARCH INITIATED 12:51:46 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 64076 TO ITERATE

100.0% PROCESSED 64076 ITERATIONS
 SEARCH TIME: 00.00.01

10 ANSWERS

L16 10 SEA SSS FUL L14

=> s 116

L17 11 L16

=> d bib abs hitstr 11

L17 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:29347 CAPLUS

DN 108:29347

TI Absorption-maximum-shifted coupler-containing conventional silver halide color photographic material and processing method

IN Ono, Mitsunori; Tamoto, Koji

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 38 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62153854	A2	19870708	JP 1985-293928	19851227
	JP 07015561	B4	19950222		
PRAI	JP 1985-293928		19851227		

AB A conventional silver halide color photog. material and a processing method therefor are claimed wherein the material comprises a coupler containing a dye moiety causing a hypsochromic shift of absorption maximum by a bond capable of breaking directly or through a timing group upon coupling reaction with an oxidized developing agent to produce a compound containing a dye moiety having the pre-shift absorption maximum and capable of further bathochromic shift by the coordination of a metal ion, and wherein the process employs a processing solution containing a metal ion(s) having a concentration

10⁻⁶ - 1.0 mol/L, character and color development.



IT 112183-82-1P

RL: PREP (Preparation)

(preparation of, as color photog. coupler, absorption-maximum-shifted)

RN 112183-82-1 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[[2-chloro-4-[[3-chloro-4-[(diethylamino)sulfonyl]phenyl]azo]-6-[(dimethylamino)(methoxyimino)methyl]phenoxy]methyl]-1-[1-[[2-chloro-5-methoxyphenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)



=> d hitstr 10

L17 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN


IT 141818-91-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antimicrobials)

RN 141818-91-9 CAPLUS

CN Benzenecarbothioic acid, S-[1-[2-[[3,4-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]amino]-1-methyl-2-oxoethyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 9

L17 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN


IT 181959-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of penem derivs. and antimicrobial agents containing them)

RN 181959-53-5 CAPLUS

CN Benzenecarbothioic acid, S-[1-[2-oxo-2-(phenylamino)ethyl]-3-pyrrolidinyl] ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 8


L17 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

IT 189005-77-4P

RL: AGR (Agricultural use); IMF (Industrial manufacture); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of herbicidal arylcarbamoylisopropylcarbamoylpyrrolinones)

RN 189005-77-4 CAPLUS

CN 1H-Pyrrole-1-acetamide, N-(3-chlorophenyl)-2,5-dihydro- $\alpha,\alpha,4$ -trimethyl-2-oxo-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)



=> d hitstr 7

L17 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN


IT 401600-90-6

RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(water-thinned jet printing inks containing water-soluble dyes with good water resistance)

RN 401600-90-6 CAPLUS

CN Benzoic acid, 3-[[[3,4-diethyl-1-[2-oxo-2-(phenylamino)ethyl]-1H-pyrrol-2-yl]carbonyl]amino]-4-methoxy-, dodecyl ester (9CI) (CA INDEX NAME)



=> d hitstr 6

L17 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

IT 479687-38-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(formylation of; preparation of kappa-agonist compound via palladium-catalyzed cross-coupling reactions)

RN 479687-38-2 CAPLUS

CN Benzamide, 4-[[[(1S)-2-[(3S)-3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]amino]-N-propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 5


L17 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

IT 497233-33-7

RL: TEM (Technical or engineered material use); USES (Uses)
(coupling agent; fluorescent photothermog. imaging element comprising)

RN 497233-33-7 CAPLUS

CN Benzoic acid, 4-chloro-3-[[2-[3-ethoxy-2,5-dioxo-4-[(phenylamino)methyl]-1-pyrrolidinyl]-3-(4-methoxyphenyl)-1,3-dioxopropyl]amino]-, dodecyl ester
(9CI) (CA INDEX NAME)



=> d hitstr 4


L17 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

IT 686347-76-2P, Benzoic acid 1-[2-phenyl-2-[[4-(propylcarbamoyl)phenyl]amino]ethyl]pyrrolidin-3-yl ester

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of pyrrolidinyl ethylamines via a copper-mediated aryl amination)

RN 686347-76-2 CAPLUS

CN Benzamide, 4-[[2-[3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



=> d hitstr 3

L17 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN


IT 741685-61-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of polysubstituted and annulated pyrroles and heteroannulated benzazepines via thermal cyclization of (dialkylamino)phosphoryl or (dialkylamino)phosphinyl allenes)

RN 741685-61-0 CAPLUS

CN 1H-Pyrrole-1-ethanamine, 2-[(diphenylphosphinyl)methyl]-3,5-diphenyl-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 2

L17 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

IT 479687-38-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(formal synthesis of κ -opioid receptor agonist CJ-15161 involving

Cu-catalyzed N-arylation)

RN 479687-38-2 CAPLUS

CN Benzamide, 4-[[[(1S)-2-[(3S)-3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]amino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 1

L17 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN


IT 881742-98-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline derivs. for use in treatment or prevention of thromboembolic diseases or tumors)

RN 881742-98-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-(4-chlorophenyl)-2-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 1

L17 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:318582 CAPLUS

DN 144:350972


TI Proline derivatives

IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes

PA Merck Patent G.m.b.H., Germany

SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034789	A1	20060406	WO 2005-EP10025	20050916
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DE 102004047255 A1 20060413 DE 2004-102004047255 20040929 PRAI DE 2004-102004047255 A 20040929 OS MARPAT 144:350972 GI				




AB The invention relates to title compds., e.g. (I), which are claimed as inhibitors of the coagulation factor Xa and can be used for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors (no data). Thus, 4-(4-aminophenyl)morpholin-3-one (II) was condensed with Boc-D-Pro-OH; the resulting intermediate was then coupled with 2-chloro-N-(5-chlorothiophen-2-yl)acetamide to give I. Schemes depicting synthesis of several alternate II starting materials are given (no data), and thirteen alternate I compds. are claimed; formulations for use as injectable forms, suppositories, salves, tablets, dragees, capsules, or ampuls are given.

IT 881742-98-9P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of proline derivs. for use in treatment or prevention of thromboembolic diseases or tumors)

RN 881742-98-9 CAPLUS


CN 1-Pyrrolidineacetamide, N-(4-chlorophenyl)-2-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 122
 L22 HAS NO ANSWERS
 L22 STR



VAR G1=AK/N/O
 VPA 17-19/20/21/22/23 U
 NODE ATTRIBUTES:
 NSPEC IS R AT 16
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8 16 4
 NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

=> s 122 ful
 FULL SEARCH INITIATED 13:00:50 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 42174 TO ITERATE

100.0% PROCESSED 42174 ITERATIONS 176 ANSWERS
 SEARCH TIME: 00.00.01

L24 176 SEA SSS FUL L22

=> fil caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
170.46	389.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.50

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 13:00:55 ON 30 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l24

L25 16 L24


=> d hitstr 16

L25 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 106742-48-7, 1-Piperidineaceto-2',6'-xylidide, 4-hydroxy-,
benzoate (ester) 106742-49-8, 1-Piperidineaceto-2',6'-xylidide,
3-hydroxy-, benzoate (ester)
(preparation of)


RN 106742-48-7 CAPLUS

CN 1-Piperidineaceto-2',6'-xylidide, 4-hydroxy-, benzoate (7CI) (CA INDEX
NAME)



RN 106742-49-8 CAPLUS

CN 1-Piperidineaceto-2',6'-xylidide, 3-hydroxy-, benzoate (7CI) (CA INDEX
NAME)



=> d hitstr 15


L25 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 53919-21-4P 53919-22-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 53919-21-4 CAPLUS

CN 1-Piperidineacetamide, N-phenyl-4-[(phenylamino)carbonyl]- (9CI) (CA
INDEX NAME)




RN 53919-22-5 CAPLUS
 CN 1-Piperidineacetamide, N-(4-methoxyphenyl)-4-[[[4-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d hitstr 14

IT 86720-08-3P 86720-67-4P 86720-74-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and gastric motility activity of)

RN 86720-08-3 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-N-(2,6-dichlorophenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-67-4 CAPLUS

CN 1-Piperidineacetamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-N-(2,6-dimethylphenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-74-3 CAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[2-(phenylamino)ethyl]-4-piperidiny]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 13

L25 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 95629-64-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antiarrhythmic activity of)

RN 95629-64-4 CAPLUS

CN 4-Piperidinecarboxamide, 4-(dimethylamino)-N-(2,6-dimethylphenyl)-1-[2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)




IT 95629-66-6P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 95629-66-6 CAPLUS

CN 1-Piperidineacetamide, 4-(dimethylamino)-N-(2,6-dimethylphenyl)-4-[[2,6-dimethylphenylamino]carbonyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



=> d hitstr 12


L25 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 104818-32-8 104818-35-1 104845-16-1
104845-17-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(opioid activity of)

RN 104818-32-8 CAPLUS

CN 1-Piperidineacetamide, 4-(benzoyloxy)-4-[(dimethylamino)methyl]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)





RN 104818-35-1 CAPLUS

CN Benzoic acid, 4-methoxy-, 4-[(dimethylamino)methyl]-1-[2-[(2,6-dimethylphenyl)amino]-2-oxoethyl]-4-piperidinyl ester, dicyclohexylsulfamate (9CI) (CA INDEX NAME)

CM 1

CRN 104818-34-0


CMF C26 H35 N3 O4



CM 2



CRN 46781-90-2

CMF C12 H23 N O3 S,





RN 104845-16-1 CAPLUS

CN Benzoic acid, 4-methoxy-, 1-[2-[(2,6-dichlorophenyl)amino]-2-oxoethyl]-4-[(dimethylamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 104845-17-2 CAPLUS
 CN Benzoic acid, 4-methoxy-, 1-[2-[(2-chloro-6-methylphenyl)amino]-2-oxoethyl]-4-[(dimethylamino)methyl]-4-piperidinyloxy ester (9CI) (CA INDEX NAME)



=> d hitstr 11


L25 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 123202-87-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and anesthetic activity of)
 RN 123202-87-9 CAPLUS
 CN 1-Piperidineacetamide, 4-(benzoyloxy)-N-(2,4,6-trimethylphenyl)- (9CI)
 (CA INDEX NAME)



IT 123202-96-0P

RN 123202-96-0 CAPLUS

CN 1-Piperidineacetamide, 4-(benzoyloxy)-N-(2,4,6-trimethylphenyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

```
=> d hitstr 10
```

L25 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 137350-43-7


RL: USES (Uses)


(coupler, photog. emulsion containing)

RN 137350-43-7 CAPLUS


CN Benzoic acid, 4-chloro-3-[[2-[3-[[2,5-dichloro-4-[[3-hexylnonyl)amino]sulfonyl]phenyl]azo]-4-methoxy-2-oxo-1(2H)-pyridinyl]-3-(4-methoxyphenyl)-1,3-dioxopropyl]amino]-, dodecyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






IT 137350-42-6P
 RL: PREP (Preparation)
 (preparation of, coupler, photog. emulsion containing)
 RN 137350-42-6 CAPLUS
 CN Benzoic acid, 3-[[2-[3-[[2,5-bis(hexyloxy)phenyl]azo]-2-oxo-1(2H)-pyridinyl]-3-(4-methoxyphenyl)-1,3-dioxopropyl]amino]-4-chloro-, dodecyl ester (9CI) (CA INDEX NAME)



=> d hitstr 9

L25 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 142209-56-1
 RL: USES (Uses)
 (yellow photog. coupler)
 RN 142209-56-1 CAPLUS
 CN 1(2H)-Pyridineacetamide, N-[5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl]amino]-2-chlorophenyl]-α-(2,2-dimethyl-1-oxopropyl)-2-oxo-6-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



=> d hitstr 8

L25 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 152332-99-5


RL: USES (Uses)

(fogging agent, for silver halide photog. material, with good dot reproductivity and storage stability)

RN 152332-99-5 CAPLUS


CN Ethanedioic acid, mono-2-propynyl ester, 2-[4-[[[3-[[[2-(benzoylimino)-1(2H)-pyridinyl]acetyl]amino]phenyl]sulfonyl]amino]phenyl]hydrazide, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B



=> d hitstr 7

L25 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 374725-01-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(pharmaceutically active piperidine derivs. as modulators of chemokine receptor activity)

RN 374725-01-6 CAPLUS

CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[2-(phenylamino)ethyl]-4-piperidiny]- (9CI) (CA INDEX NAME)




IT 374725-06-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutically active piperidine derivs. as modulators of chemokine receptor activity)

RN 374725-06-1 CAPLUS

CN Benzeneacetamide, N-ethyl-4-fluoro-N-[1-[2-(phenylamino)ethyl]-4-piperidiny]- (9CI) (CA INDEX NAME)



=> d hitstr 6

L25 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 374725-01-6P 374725-06-1P 463934-36-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel N-(2-piperidinoethyl) amides as modulators of chemokine receptors)


RN 374725-01-6 CAPLUS

CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[2-(phenylamino)ethyl]-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 374725-06-1 CAPLUS

CN Benzeneacetamide, N-ethyl-4-fluoro-N-[1-[2-(phenylamino)ethyl]-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 463934-36-3 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-methyl-N-[1-[2-(phenylamino)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



=> d hitstr 5

L25 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 496058-36-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(NMDA receptor antagonist; preparation of piperidinylacetamides by coupling reactions as NMDA receptor antagonists)

RN 496058-36-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(methylphenylamino)methyl]-N-[4-[(methylsulfonyl)amino]phenyl]-α-oxo- (9CI) (CA INDEX NAME)



=> d hitstr 4

L25 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN



IT 615577-39-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinone and pyrimidinone derivs. for use as Lp-PLA2 inhibitors in the treatment of atherosclerosis)

RN 615577-39-4 CAPLUS

CN 1(4H)-Quinolineacetamide, N-[1-[2-[(3-cyanophenyl)amino]-2-oxoethyl]-4-piperidinyl]-2-[[[(2,3-difluorophenyl)methyl]thio]-4-oxo-N-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



=> d hitstr 3

L25 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 820996-25-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyrrolidinium and piperidinium quaternary salts as muscarinic M3 receptor antagonists)


RN 820996-25-6 CAPLUS

CN Piperidinium, 4-[(hydroxydiphenylacetyl)oxy]-1-methyl-1-[2-oxo-2-(phenylamino)ethyl]-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 820996-24-5


CMF C28 H31 N2 O4



CM 2

CRN 14477-72-6

CMF C2 F3 O2



=> d hitstr 2

L25 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 860169-99-9P 860170-02-1P 860170-05-4P

860170-08-7P 860170-11-2P 860170-14-5P

860170-17-8P 860170-19-0P 860170-22-5P

860170-25-8P 860170-28-1P 860170-31-6P

860170-34-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; asym. synthesis of norcisapride quinuclidinol derivs. for use in pharmaceutical compns. for the treatment of gastrointestinal and central nervous system disorders)

RN 860169-99-9 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidiny]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860170-02-1 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidiny]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860170-05-4 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860170-08-7 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860170-11-2 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 2-methoxyethyl ester (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 860170-14-5 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 2-(1-pyrrolidinyl)ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 860170-17-8 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 1-methyl-4-piperidinyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 860170-19-0 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 2-(2-pyridinyl)ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 860170-22-5 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 2-(dimethylamino)ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 860170-25-8 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 1-methyl-3-piperidinyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 860170-28-1 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 2-(4-morpholinyl)ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 860170-31-6 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 1,4-dimethyl-4-piperidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860170-34-9 CAPLUS

CN Benzoic acid, 4-[[[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-1-piperidinyl]acetyl]amino]-, 2-oxo-2-(4-piperidinylamino)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 1

L25 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 882688-61-1P 882688-62-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors)


RN 882688-61-1 CAPLUS

CN 1(2H)-Pyridineacetamide, N-[1,1'-biphenyl]-4-yl-2-oxo-3-(phenylmethoxy)-(9CI) (CA INDEX NAME)





RN 882688-62-2 CAPLUS

CN 1(2H)-Pyridineacetamide, 2-oxo-N-(4-phenoxyphenyl)-3-(phenylmethoxy)-(9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:97412 CAPLUS
 DN 138:153539
 TI Preparation of 2-(piperidin-1-yl)acetamides as NMDA receptor antagonists
 IN Domany, Gyoergy; Horvath, Csilla; Farkas, Sandor; Barta Szalai, Gisella;
 Nagy, Jozsef; Kolok, Sandor; Kovacs Bozo, Eva; Borza, Istvan; Vago,
 Istvan; Bielik, Attila; Szendrei, Mrs. Gyorgyi Ignaczne; Keseru, Gyorgy
 PA Richter Gedeon Vegyeszeti Gyar Rt., Hung.
 SO PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003010159	A1	20030206	WO 2002-HU71	20020723
	WO 2003010159	C1	20040212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2453383	AA	20030206	CA 2002-2453383	20020723
	EE 200400058	A	20040415	EE 2004-58	20020723
	EP 1409477	A1	20040421	EP 2002-753161	20020723
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2002011393	A	20040817	BR 2002-11393	20020723
	CN 1556805	A	20041222	CN 2002-814234	20020723
	JP 2005515968	T2	20050602	JP 2003-515518	20020723
	NZ 530055	A	20050729	NZ 2002-530055	20020723
	ZA 2004000417	A	20050518	ZA 2004-417	20040120
	US 2004157886	A1	20040812	US 2004-761940	20040121
	NO 2004000307	A	20040323	NO 2004-307	20040123
	BG 108592	A	20050331	BG 2004-108592	20040220
PRAI	HU 2001-3055	A	20010724		
	HU 2002-2213	A	20020710		
	WO 2002-HU71	W	20020723		
OS	MARPAT 138:153539				
GI					



AB The title compds. I [wherein V and U = independently H, halo, OH, CN, NO₂, NH₂, alkylsulfonyloxy, carboxyl, CF₃, CF₃O, alkyl-SO₂-NHCH₂, NH₂-(CH₂)₁₋₄-SO₂NH, NH₂-(CH₂)₁₋₄-CONH, sulfamoyl, CHO, aminomethyl, HOCH₂, alkyl, alkoxymethyl, halo-CH₂, tetrazolyl, alkoxy(carbonyl), alkanoyloxy, Ph, (un)substituted alkylamino, arylamino, aralkylamino, alkylsulfonamido, alkanoylamido, arylsulfonamido, or alkoxy groups; or the neighboring V and U together form (un)substituted 4-7 membered ring with the atoms attached; W and X = independently CO, CH₂, or CH-alkyl; Y = O, (cyclo)alkylene, alkynylene, aminocarbonyl, NH, N-alkyl, CH₂O, CH(OH), or OCH₂; Z = H, halo, NO₂, NH₂, alkyl, alkoxy, CN, CF₃, OH, or CO₂H; R₁ and R₂ = independently H or alkyl; or R₁ and R₂ together form (un)substituted C₁-C₃ bridge; n and m = independently 0-3 with restriction that n and m ≠ 0 at the same time; with provisos] and optical antipodes, racemates, or pharmaceutically acceptable salts thereof are prepared as NMDA receptor antagonists, and moreover most of the compds. are selective antagonist of NR2B subtype of NMDA receptor. For example, 2-[4-(4-fluorobenzyl)piperidin-1-yl]-2-oxoacetic acid (prepn given) was treated with 5-amino-1,3-dihydroindol-2-one in DMF in the presence of Et₃N and HBTU to afford the acetamide II (48%). II showed IC₅₀ of 0.0007 μM against NMDA in rat. Formulations containing I as an active ingredient were also described.


IT 496058-36-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(NMDA receptor antagonist; preparation of piperidinylacetamides by coupling reactions as NMDA receptor antagonists)

RN 496058-36-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(methylphenylamino)methyl]-N-[4-[(methylsulfonyl)amino]phenyl]-α-oxo- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT